微信公众号
证券之星APP
| 报告期 | 净资产收益率 | 同比 | 环比 | 行业排名 | 行业均值 | 行业龙头股 | 龙头股该指标值 | 查看 |
|---|---|---|---|---|---|---|---|---|
| 2025-09-30 | 7.09% | -11.38% | 55.48% | 41/159 | 1.2% | 兴齐眼药 | 32.91% | 行业排名> |
| 2025-06-30 | 4.56% | 24.93% | 54.58% | 36/159 | 0.26% | 翰宇药业 | 18.95% | 行业排名> |
| 2025-03-31 | 2.95% | -5.14% | -65.05% | 35/159 | -0.37% | 翰宇药业 | 11.39% | 行业排名> |
| 2024-12-31 | 8.44% | 50.71% | 5.5% | 38/159 | -9.52% | 百利天恒 | 181.27% | 行业排名> |
| 2024-09-30 | 8% | 41.09% | 119.18% | 39/159 | 4.23% | 百利天恒 | 186.1% | 行业排名> |
| 2024-06-30 | 3.65% | -9.43% | 17.36% | 56/159 | 2.66% | 百利天恒 | 186.89% | 行业排名> |
| 2024-03-31 | 3.11% | 56.28% | -44.46% | 28/159 | 2.32% | 百利天恒 | 188.56% | 行业排名> |
| 2023-12-31 | 5.6% | -61.22% | -1.23% | 58/159 | -1.03% | 小方制药 | 41.8% | 行业排名> |
| 2023-09-30 | 5.67% | -61.53% | 40.69% | 59/159 | 2.34% | 拓新药业 | 20.51% | 行业排名> |
| 2023-06-30 | 4.03% | -62.86% | 102.51% | 51/159 | 1.46% | 拓新药业 | 19.87% | 行业排名> |
| 2023-03-31 | 1.99% | -69% | -86.22% | 62/159 | 1.37% | 拓新药业 | 19.91% | 行业排名> |
| 2022-12-31 | 14.44% | 76.53% | -2.04% | 20/159 | 0.67% | 小方制药 | 55.57% | 行业排名> |
| 2022-09-30 | 14.74% | 21.52% | 35.85% | 9/159 | 2.8% | 福元医药 | 25.41% | 行业排名> |
| 2022-06-30 | 10.85% | 126.99% | 69% | 8/159 | 2.16% | 小方制药 | 34.81% | 行业排名> |
| 2022-03-31 | 6.42% | 105.11% | -21.52% | 4/159 | 1.57% | 退市金泰 | 10.74% | 行业排名> |
| 2021-12-31 | 8.18% | -17.95% | -32.56% | 55/159 | 0.75% | 人福医药 | 6.82% | 行业排名> |
| 2021-09-30 | 12.13% | 10.17% | 153.77% | 20/159 | 4.43% | 小方制药 | 71.99% | 行业排名> |
| 2021-06-30 | 4.78% | -36.86% | 52.72% | 57/159 | 2.94% | 汇宇制药 | 39.25% | 行业排名> |
| 2021-03-31 | 3.13% | -9.54% | -68.61% | 39/159 | 2.49% | 汇宇制药 | 28.14% | 行业排名> |
| 2020-12-31 | 9.97% | -49.57% | -9.45% | 55/159 | 3.58% | 哈三联 | 27.17% | 行业排名> |
| 2020-09-30 | 11.01% | -40.13% | 45.44% | 32/159 | 3.03% | 汇宇制药 | 55.94% | 行业排名> |
| 2020-06-30 | 7.57% | -43.42% | 118.79% | 30/159 | 4.19% | 河化股份 | 45.32% | 行业排名> |
| 2020-03-31 | 3.46% | -56.42% | -82.5% | 25/159 | 2.19% | 汇宇制药 | 31.9% | 行业排名> |
| 2019-12-31 | 19.77% | -2.08% | 7.5% | 19/159 | 2.53% | 誉衡药业 | 35.56% | 行业排名> |
| 2019-09-30 | 18.39% | 13.03% | 37.44% | 6/159 | 7.48% | 奥赛康 | 35% | 行业排名> |
| 2019-06-30 | 13.38% | 23.89% | 68.51% | 6/159 | 4.96% | 奥赛康 | 28.15% | 行业排名> |
| 2019-03-31 | 7.94% | -12.56% | -60.67% | 5/159 | 2.41% | 宏源药业 | 21.91% | 行业排名> |
| 2018-12-31 | 20.19% | 33.44% | 24.09% | 14/159 | 6.99% | 奥赛康 | 9.7% | 行业排名> |
| 2018-09-30 | 16.27% | 25.93% | 50.65% | 7/159 | 7.18% | 奥赛康 | 40.69% | 行业排名> |
| 2018-06-30 | 10.8% | 18.55% | 18.94% | 9/159 | 4.6% | 信立泰 | 25.93% | 行业排名> |
| 2018-03-31 | 9.08% | 237.55% | -39.99% | 3/159 | 2.54% | 昂利康 | 15.91% | 行业排名> |
| 2017-12-31 | 15.13% | 188.19% | 17.11% | 26/159 | 9.61% | 奥赛康 | 12.08% | 行业排名> |
| 2017-09-30 | 12.92% | 251.09% | 41.82% | 19/159 | 8.29% | 一品红 | 31.62% | 行业排名> |
| 2017-06-30 | 9.11% | 397.81% | 238.66% | 19/159 | 5.58% | 丽珠集团 | 49.43% | 行业排名> |
| 2017-03-31 | 2.69% | 355.93% | -48.76% | 33/159 | 2.09% | 河化股份 | 54.24% | 行业排名> |
| 2016-12-31 | 5.25% | 683.58% | 42.66% | 81/159 | 6.19% | 华东医药 | 7.2% | 行业排名> |
| 2016-09-30 | 3.68% | 682.98% | 101.09% | 62/159 | 5.61% | 南新制药 | 81.7% | 行业排名> |
| 2016-06-30 | 1.83% | 83% | 210.17% | 69/159 | 3.48% | 德展健康 | 29.5% | 行业排名> |
| 2016-03-31 | 0.59% | -22.37% | -11.94% | 69/159 | 2.65% | 贝达药业 | 16.78% | 行业排名> |
| 2015-12-31 | 0.67% | -87.14% | 42.55% | 90/159 | 11.27% | 河化股份 | 19.29% | 行业排名> |
| 2015-09-30 | 0.47% | -86.3% | -53% | 72/159 | 7.22% | 一品红 | 58.17% | 行业排名> |
| 2015-06-30 | 1% | -53.05% | 31.58% | 65/159 | 4.87% | 华东医药 | 36.97% | 行业排名> |
| 2015-03-31 | 0.76% | 7.04% | -85.41% | 55/159 | 2.41% | 华东医药 | 26.63% | 行业排名> |